Saturday 17 October 2026
Export NDRA’s income statement to Excel — free account
ENDRA Life Sciences Inc.
NDRA Healthcare Diagnostics & Research
In the quarter to June 2026, EPS grew 107.0% and free cash flow grew 15.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
4.74
0.36
−7.06%
Follow NDRA
ENDRA Life Sciences Inc. (NDRA) P/E ratio
ENDRA Life Sciences Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2018 | 0.0× | — |
| Dec 2017 | 0.0× | — |
| Sep 2017 | 0.0× | — |
| Jun 2017 | 0.0× | — |
| 1 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DMTKQ DermTech, Inc. compare | n/m |
| NOTVQ Inotiv, Inc. compare | n/m |
| TTOO T2 Biosystems, Inc. compare | n/m |
| PMD Psychemedics Corporation compare | n/m |
| XWEL XWELL, Inc. compare | n/m |
| ISPC iSpecimen Inc. compare | n/m |
| NDRA ENDRA Life Sciences Inc. | n/m |
| BIAF bioAffinity Technologies, Inc. compare | n/m |
| ADVB Advanced Biomed Inc. compare | 0.8× |
| Diagnostics & Research industry median | 35.6× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)